In this issue:
- Fixed-duration acalabrutinib combinations in untreated CLL
- Biomarker signature of CAR T-cell response in non-Hodgkin lymphoma
- Reducing venetoclax to 7 days in newly diagnosed AML
- Zanubrutinib-based regimens for relapsed/ refractory primary CNS lymphoma
- Zanubrutinib vs. bendamustine-rituximab in treatment-naïve CLL
- Talquetamab for relapsed/ refractory MM
- Hypercalcaemia in MGUS
- Daratumumab with lenalidomide as post transplant maintenance in newly diagnosed MM
- Adding pomalidomide to bortezomib-dexamethasone in relapsed/refractory MM
- Predictive value of free light chain burden in bortezomib treated AL amyloidosis
Please login below to download this issue (PDF)